Welcome to our dedicated page for ymtx news (Ticker: ymtx), a resource for investors and traders seeking the latest updates and insights on ymtx stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect ymtx's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of ymtx's position in the market.
Yumanity Therapeutics (YMTX) announced a partial clinical hold on its multicenter clinical trials for YTX-7739, a Parkinson’s disease treatment, following FDA feedback on its recent IND application. While the initiation of multiple dose trials is suspended, the planned single dose trial will proceed. The FDA is expected to provide further details within 30 days, and Yumanity will collaborate closely to address the agency's concerns. YTX-7739 aims to inhibit stearoyl-CoA desaturase to mitigate neurotoxicity associated with alpha-synuclein protein accumulation.
Yumanity Therapeutics recently achieved a significant milestone in its collaboration with Merck, resulting in a $5 million milestone payment for their joint ALS/FTLD program. Additionally, the company received a $500,000 grant from the Michael J. Fox Foundation to expedite proof-of-concept testing for its Parkinson's disease therapy, YTX-7739. This therapy is currently in Phase 1 clinical development, and a randomized Phase 2 trial is expected to commence in 2022. Yumanity's pipeline includes various neurodegenerative disease programs, enhancing its market position.
Yumanity Therapeutics (NASDAQ: YMTX) announced the grant of non-statutory stock options for up to 11,000 shares to an employee, with an exercise price of $3.27 per share. The options will vest over four years, starting with 25% after the first year. This grant supports the company's strategy of attracting talent through equity incentives. Yumanity is focused on innovative therapies for neurodegenerative diseases, including its leading candidate YTX-7739, currently in Phase 1 for Parkinson’s disease. The company’s pipeline includes treatments for various neurodegenerative disorders.
Yumanity Therapeutics (NASDAQ: YMTX), a clinical-stage biopharmaceutical company, will have its CEO, Richard Peters, present at the H.C. Wainwright BioConnect Conference, scheduled for January 10-13, 2022. The presentation will be available on-demand starting January 10 at 7 a.m. EST through the conference portal and Yumanity's website. The company is focused on developing therapies for neurodegenerative diseases, with its leading candidate, YTX-7739, in clinical trials for Parkinson’s disease.
Yumanity Therapeutics (NASDAQ: YMTX) announced the grant of non-statutory stock options to one employee for the purchase of up to 2,000 shares of common stock at an exercise price of $3.83. The options will vest over four years, with 25% vesting on the first anniversary and the remainder vesting monthly thereafter. This grant complies with Nasdaq Listing Rule 5635(c)(4) as an inducement for employment. Yumanity is engaged in developing therapies for neurodegenerative diseases, with its lead candidate, YTX-7739, in Phase 1 for Parkinson's disease.
BOSTON, Nov. 16, 2021 – Yumanity Therapeutics (NASDAQ: YMTX) announced that CEO Richard Peters will present at key investor conferences this November, discussing the Phase 1b study results of YTX-7739 for Parkinson's disease.
Upcoming Events:
- Stifel Healthcare Conference: Nov 17, 9:20 a.m. EST
- Jefferies London Healthcare Conference: Nov 16-18, Nov 18 at 3:00 a.m. EST
- Piper Sandler Annual Healthcare Conference: Nov 30-Dec 2, Nov 22 at 10:00 a.m. EST
Webcasts available at Yumanity website.
Yumanity Therapeutics (NASDAQ: YMTX) announced successful Phase 1b trial results for YTX-7739 in Parkinson’s disease patients, noting good tolerability and favorable PK/PD profiles. The company plans to initiate a Phase 2 trial in 2022, supported by the promising exploratory qEEG data indicating potential improvements in synaptic function. Financially, Yumanity reported a net loss of $10.0 million for Q3 2021, with cash reserves of $46.4 million, expected to fund operations into Q3 2022. Michael D. Wyzga was appointed as CFO to strengthen the management team.
Yumanity Therapeutics (NASDAQ: YMTX) announced the grant of stock options to two employees for up to 2,000 shares of common stock, vesting over four years. The options have an exercise price of $9.27 per share, matching the closing price on November 1, 2021. This grant is part of Yumanity’s 2021 Inducement Plan, adhering to Nasdaq Listing Rule 5635(c)(4). Yumanity is focused on developing therapies for neurodegenerative diseases, with its lead candidate, YTX-7739, currently in Phase 1 clinical trials for Parkinson’s disease.
Yumanity Therapeutics (Nasdaq: YMTX) announced successful results from the Phase 1b clinical trial of its lead product candidate, YTX-7739, for treating mild-to-moderate Parkinson's disease. The trial met primary endpoints, demonstrating favorable pharmacokinetic and pharmacodynamic profiles, with no serious adverse events reported. YTX-7739 effectively inhibited its target enzyme, stearoyl-CoA desaturase (SCD), leading to relevant reductions in the fatty acid desaturation index. Management is optimistic about advancing to Phase 2 trials in 2022.
Yumanity Therapeutics (NASDAQ: YMTX) announced the grant of non-statutory stock options to an employee for the purchase of 4,000 shares. The options will vest over four years, with an exercise price set at $10.48, matching the stock's closing price on the grant date, October 1, 2021. This grant aligns with Nasdaq Listing Rule 5635(c)(4) as an inducement for the new hire. Yumanity focuses on developing therapies for neurodegenerative diseases, including Parkinson’s, ALS, and Alzheimer’s, utilizing a drug discovery platform to overcome challenges in treating such conditions.
